Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Bowen PanCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.ORCID 0000-0003-0930-4492
Tao WangCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Liangliang ZhengCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Zhangchao DongCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Lijuan LiuCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Xiongwei LiuCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Tingting FengCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Ying ZhouCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Yang ShiCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Funding
Guizhou Province Innovation Talent Team Construction for the Efficient and Comprehensive Utilization of Unique Food and Medicinal Materials Platform Talent-CXTD[2023]020Guizhou Provincial Basic Research Program (Natural Science) ZK[2023] general 404Guizhou Provincial Basic Research Program (Natural Science) ZK [2024] general 370Natural Science Research Project of Guizhou Department of Education Qianjiaoji [2023] 069the Guiyang City Science and Technology Plan Project NO. [2024]2-37the High-level Innovative Talents of Guizhou Province QianKeHe platform talents-GCC [2023] 047the projects of Guizhou province gzwkj2022-232 and gzwkj2022-467the Research Project on Traditional Chinese Medicine and Ethnic Medicine Science and Technology of Guizhou Provincial Administration of Traditional Chinese Medicine QZYY-2024-130the State Key Laboratory of Natural and Biomimetic Drugs K202222
6 · The paper itself
Abstract
A synthetic strategy of a three-component spiro-pyrrolidine compound based on benzofuran via an [3+2] azomethine ylide cycloaddition reaction is reported herein. Under mild optimal conditions, this reaction can quickly produce potentially bioactive compounds with a wide range of substrates, high yield, and simple operation. The desired products were obtained with a yield of 74-99% and a diastereomeric ratio (dr) of >20:1. Subsequently, the inhibitory effects of the compounds on the cell viability of the human cancer cell line HeLa and mouse cancer cell line CT26 were evaluated. Compounds
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Synthesis of Novel Benzofuran Spiro-2-Pyrrolidine Derivatives via [3+2] Azomethine Ylide Cycloadditions and Their Antitumor Activity. · full record | OpenQuestion